Abstract 415P
Background
RET fusion is one of the rare driver genes in lung cancer and thyroid carcinoma and and RET-directed therapies have shown promising results in this unique population. The aim of this study was to investigate the efficacy of cabozantinib in patients with advanced RET fusion NSCLC.
Methods
A multicenter study in China was initiated from February 2014, and NSCLC patients have been enrolled as of December 2019. To determine the frequency of the RET fusions in NSCLC and other tumors, we analyzed data from 3046 clinical NSCLC cases, each of which had results from next-generation sequencing (NGS)-based 381 genes panel assay, analogous to the index patient.
Results
Of this entire cohort, 61 (2.00%) patients were identified with a RET fusion, including KIF5B-RET (40), CCDC6-RET (16), NCOA4-RET (1), ANK3-RET (1), ERC1-RET (1), RYFY2-RET (1) and CSGALNACT2-RET (1). 8 cases coexist with EGFR mutations, were all used EGFR-TKIs treatment. For treatments, 14.75% (9/61) patients chose cabozantinib, other patients chose chemotherapy or chemoradiotherapy, and case examples of advanced RET fusion driven NSCLC patients responding to cabozantinib were actively being sought thru our database.
Conclusions
Patients with advanced RET fusion NSCLC showed a relatively good outcome of cabozantinib with relatively large side effects, which strengthen the need for effective RET-targeted drugs in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chun-wei Xu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
424P - Hippocampus sparing in volumetric modulated arc therapy (VMAT) for brain tumour radiotherapy treatment
Presenter: Eva Yi Wah Cheung
Session: e-Poster Display Session
425P - The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents
Presenter: Chun Loo Gan
Session: e-Poster Display Session
426P - A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
Presenter: Marcia S. Brose
Session: e-Poster Display Session
427P - On the clinical implications of systemic and local immune responses in human angiosarcoma
Presenter: Jason Yongsheng Chan
Session: e-Poster Display Session
428P - Prognostic value of clinico-pathological characteristics and peripheral monocyte counts in localised extra-meningeal solitary fibrous tumours treated with surgical resection
Presenter: Ryan Lim
Session: e-Poster Display Session
429P - Demographics, pattern of care, and outcome analysis of malignant melanoma cases from a tertiary care centre in India
Presenter: Anshul Agarwal
Session: e-Poster Display Session
430P - Teenagers and young adult cancers in rural central India: Access to age-appropriate care
Presenter: Runu Sharma
Session: e-Poster Display Session
431P - Quantitative study of two critical lncRNAs in patients with glioma tumours
Presenter: Kamal Mohammadian
Session: e-Poster Display Session
432P - Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma
Presenter: Mustafa Gürbüz
Session: e-Poster Display Session
433P - Association between aspirin and cancer risk: A Mendelian randomization analysis
Presenter: Yu Jiang
Session: e-Poster Display Session